More Than A Magazine, A Movement
The future of mifepristone access is up in the air on multiple fronts right now—just five months after the U.S. Supreme Court rejected a challenge to the U.S. Food and Drug Administration’s treatment of the medication abortion drug.
Now, though, Donald Trump has won election to the presidency—and questions about what his new administration will do to federal policy surrounding the drug are front and center.
House Speaker Mike Johnson on Wednesday issued a statement purporting to ban transgender women from women’s restrooms and transgender men from men’s restrooms throughout the Capitol and House office buildings.
The policy announcement from the Republican House leader was the latest move in a multi-day attack on Sarah McBride, a Democrat elected to represent Delaware in the House who will be the first out transgender member of Congress. The move also comes in the midst of attacks on transgender people more broadly—in legislation and campaigns, and elsewhere—and just weeks before the U.S. Supreme Court is due to hear a major case over the constitutionality of anti-trans laws banning gender-affirming medical care for minors.
The Justice Department went to the U.S. Supreme Court this week in defense of the Biden administration’s new Title IX sex discrimination rule that includes transgender protections—arguing strongly that the logic of the rule is “compelled” by the Court’s ruling in Bostock.
The rule, issued under Title IX of the Education Amendments Act of 1972, is set to go into effect on Aug. 1.
Monday was a day bookended by reminders that Donald Trump expects and rewards obedience—from Cannon’s Florida ruling, to Trump’s VP pick of JD Vance.
